RT Journal Article
SR Electronic
T1 Hospitalizations, resource use and outcomes of acute pulmonary embolism in Germany during the Covid-19 pandemic Emergence of different phenotypes of thrombotic disease?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.08.21250291
DO 10.1101/2021.02.08.21250291
A1 Husser, Daniela
A1 Hohenstein, Sven
A1 Pellissier, Vincent
A1 König, Sebastian
A1 Ueberham, Laura
A1 Hindricks, Gerhard
A1 Meier-Hellmann, Andreas
A1 Kuhlen, Ralf
A1 Bollmann, Andreas
A1 on behalf of Helios hospitals, Germany
YR 2021
UL http://medrxiv.org/content/early/2021/02/11/2021.02.08.21250291.abstract
AB Background There is discussion evolving around the emergence of different phenotypes of Covid-19-associated thromboembolic disease, i.e. acute pulmonary embolism vs pulmonary thrombosis and different phenotypes of in situ thrombosis. With this study, we wish to provide hospitalization, treatment and in-hospital outcome data for pulmonary embolism during the 2020 Covid-19 pandemic and a corresponding 2016 – 2019 control period.Methods We performed a retrospective analysis of claims data of Helios hospitals in Germany. Consecutive cases with a hospital admission between January 1 and December 15, 2020 and pulmonary embolism as primary discharge diagnosis were analyzed and compared to a corresponding period covering the same weeks in 2016 – 2019.Results As previously reported for other emergent medical conditions, there was a hospitalization deficit coinciding with the 1st pandemic wave. Beginning with the 12-week interval May 6 – July 28, there was a stable surplus of hospital admissions in 2020. During this surplus period (May 6 – December 15, 2020), there were 2,449 hospitalizations including 45 PCR-confirmed Covid-19 cases (1.8%) as opposed to 8,717 in 2016 – 2019 (IRR 1.12, 95% CI 1.07 – 1.18, P<0.01). When excluding Covid-19 cases IRR was 1.10 (95% CI 1.05 – 1.15, P<0.01). While overall comorbidities expressed as weighted AHRQ Elixhauser Comorbidity Index (14.1 ± 10.1 vs. 13.9 ±10.3, P=0.28), the presence of thrombosis (46.1 vs 45.4%, P=0.55) and surgery (3.8 vs. 4.3%, P=0.33) were comparable, coagulopathy (3.3 vs 4.5%, P=0.01) and metastatic cancer (3.0 vs 4.0%, P=0.03) as contributing factors were less frequently observed during the 2020 surplus. Interventional treatments (thrombolytic therapy, thrombectomy or inferior vena cava filter placement) were less frequently used (4.7 vs 6.6%, OR 0.72, 95% CI 0.58 − 0.89, P< 0.01). Similarly, intensive care (35.1 vs 38.8%, OR 0.83, 95% CI 0.75 − 0.92, P< 0.01) and mechanical ventilation utilization (7.2 vs 8.1%, OR 0.88, 95% CI 0.74 – 1.04, P=0.14) as well as in-hospital-mortality rates (7.8 vs 9.8%, OR 0.76, 95% CI 0.64 − 0.90, P< 0.01) were lower in 2020 compared with 2016 – 2019. This was associated with a shorter length of hospital stay (6.4 ±5.4 vs. 7.2 ±5.7 days, P< 0.01) during the 2020 surplus period.Conclusions Only a minority of cases were associated with PCR-confirmed Covid-19 but this does not rule out preceding or undetected SARS-CoV-2 infection. Although there is a shift towards milder disease course, the increased incidence of hospitalizations for pulmonary embolism requires immediate attention, close surveillance and further studies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee at the Medical Faculty, Leipzig University (#490/20-ek). Due to the retrospective study of anonymized data informed consent was not obtained.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author.